Biomarker-Guided PARP Inhibitor Selection for Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breast cancer, particularly in determining effective therapeutics, face challenges such as high production costs, drug resistance, chemotherapy complications, and safety issues, making it difficult to establish the efficacy of drugs without trial and error, and there is a need for methods to select optimal therapeutic agents.
Innovation Solution
The method involves measuring protein levels of specific biomarkers in pre-treatment tumor samples using techniques like RPPA, immunihistochemistry, or ELISA to predict the efficacy of PARP inhibitors by comparing them to baseline values, identifying subjects likely to respond to PARP therapeutic agents, and administering an effective amount of the therapeutic agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics are used for breast cancer treatment, then treatment coverage is broad, but efficacy cannot be established without trial and error and production costs are high
Solution Approach 1:
The patent performs preliminary biomarker analysis on tumor samples before treatment to predict which therapeutic agents will be effective. This advance characterization of tumor molecular profile allows clinicians to select the most appropriate therapy beforehand, eliminating the need for trial-and-error treatment approaches and reducing overall treatment complexity.
Solution Approach 2:
The patent introduces biomarkers as intermediary indicators that mediate between tumor characteristics and therapeutic response. By measuring specific biomarker expressions in tumor samples, the system translates complex tumor biology into actionable predictive information that guides therapeutic selection, serving as an intermediary layer between diagnosis and treatment.
2Reliability
If multiple therapeutic agents are tested to determine efficacy, then optimal treatment can be identified, but treatment time increases and patient exposure to ineffective drugs increases
Solution Approach 1:
The patent performs preliminary biomarker analysis on tumor samples before treatment to predict which therapeutic agents will be effective. This advance characterization of tumor molecular profile allows clinicians to select the most appropriate therapy beforehand, eliminating the need for trial-and-error treatment approaches and reducing overall treatment complexity.
3Reliability
If broad-spectrum chemotherapy is administered, then all cancer cells may be targeted, but complications and safety issues increase
Solution Approach 1:
The patent applies the principle of local quality by matching specific therapeutic agents to specific tumor molecular characteristics identified through biomarker analysis. Instead of applying uniform broad-spectrum chemotherapy to all patients, the treatment is tailored to the local molecular profile of each patient's tumor, targeting cancer cells with precision while sparing normal tissues from unnecessary exposure to toxic agents.
Solution Approach 2:
The patent changes the fundamental parameter of treatment selection from empirical broad-spectrum approach to molecularly-guided specific approach. By altering the selection criterion from general cancer diagnosis to specific biomarker profile, the system enables precise targeting of cancer cells while minimizing exposure of normal cells to chemotherapy complications.
Data Source
AI summary
Disclosed herein are methods for treating subjects with breast cancer, comprising determining a therapeutic regimen for cancer by measuring the level (amount) of proteins of one or more biomarkers. Also disclosed are methods of treating a subject with breast cancer by predicting or assessing a therapeutic outcome for subject.